MLKL and inflammatory bowel disease: Given the ongoing development of RIPK1 inhibitors, it is noteworthy that phosphorylated MLKL coincided with phosphorylated RIPK1 in some, but not all patients with IBD (patients D versus H in Fig. 6C).